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Objective: Vascular dysfunction represents a disease initiating event in scleroderma 
(SSc). Recent data suggest that epigenetic dysregulation impairs normal angiogenesis 
and can result in abnormal blood vessel growth patterns. Histone deacetylases (HDACs) 
control endothelial cell (EC) proliferation and regulate EC migration. Specifically, 
HDAC5 appears to be anti-angiogenic. We hypothesized that HDAC5 contributes to 
impaired angiogenesis in SSc by repressing pro-angiogenic factors in ECs.  
Methods: Dermal ECs were isolated from patients with diffuse cutaneous SSc and 
healthy controls. Angiogenesis was assessed by an in vitro Matrigel tube formation 
assay. An assay for transposase-accessible chromatin using sequencing (ATAC-seq) 
was performed to assess and localize genome-wide effects of HDAC5 knockdown on 
chromatin accessibility.  
Results: The expression of HDAC5 was significantly increased in SSc ECs compared 
to normal ECs. Silencing of HDAC5 in SSc ECs restored normal angiogenesis. HDAC5 
knockdown followed by ATAC-seq in SSc ECs identified key HDAC5-regulated genes 
involved in angiogenesis and fibrosis, such as CYR61, PVRL2, and FSTL1. 
Simultaneous knockdown of HDAC5 with either CYR61, PVRL2, or FSTL1 inhibited 
angiogenesis in SSc ECs while overexpression of these genes individually led to 
increase in tube formation in Matrigel assay, suggesting that these genes play 
functional roles in impairing angiogenesis in SSc. 
Conclusions: Several novel HDAC5-target genes associated with impaired 
angiogenesis were identified in SSc ECs by ATAC-seq. This study provides a link 
between epigenetic regulation and impaired angiogenesis in SSc, and identifies a novel 
mechanism for dysregulated angiogenesis that characterizes this disease.  
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Systemic sclerosis (scleroderma, SSc) is a poorly understood autoimmune 
disease characterized by vascular injury and debilitating tissue fibrosis. Activation of 
endothelial cells (ECs), inflammatory cells, as well as fibroblasts leads to excessive 
production of extracellular matrices that accumulate in various organs. Widespread 
vascular damage appears to be an early disease event as morphological changes in the 
vasculature occur before the onset of tissue fibrosis. This is supported by the early 
presentation of Raynaud's phenomenon, a condition that occurs as the first symptom in 
almost all SSc patients, prior to the occurrence of fibrosis. Other vascular complications 
include pulmonary arterial hypertension and scleroderma renal crisis, both of which 
contribute significantly to mortality in SSc (1).  
In the skin, SSc vasculopathy leads to loss of dermal capillaries resulting in 
tissue hypoxia and ischemia, which under normal circumstances, prompts angiogenesis. 
However, in SSc this compensatory process is impaired and the ECs are incapable of 
building new blood vessels (2). The mechanism of dysregulated angiogenesis in SSc 
ECs appears to be multifactorial: the expression of angiogenic-related proteins and 
transcription factors is altered (2-4), impairment of the urokinase-type plasminogen 
activator receptor pathway is evident (2), defects in the basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF) pathway are present (2, 5-7), 
and changes in chemokine and chemokine receptor expression and signaling occur (2, 
4, 8). In addition, SSc ECs can promote fibroblast activation via the CCN2/TGFβ 
pathway (9). Epigenetic mechanisms in SSc ECs dysfunction is also noted, as the lower 
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expression of bone morphogenetic protein receptor II (BMPR II) in these cells can be 
modified by inhibitors of DNA methyltransferase and histone deacetylase (HDAC) (10).  
Emerging data on the role of epigenetics in angiogenesis are beginning to shed 
light on abnormal angiogenesis in different diseases. Specifically, HDACs, which 
enzymatically remove acetyl groups from histones, appear to play significant roles in 
blood vessel formation. It was reported that non-selective inhibitors of HDACs reduce 
tube formation of EC in vitro, inhibit postnatal neovascularization in response to hypoxia, 
and block tumor angiogenesis (11). Moreover, the enzymatic activity of class I and II 
HDACs is essential for endothelial commitment of progenitor cells (11). Studies that 
examined individual HDACs in ECs revealed that class IIa HDACs (HDAC5, 7, and 9), 
class IIb HDACs (HDAC6), as well as class III HDACs (SIRT1) are involved in 
angiogenesis (11). They have been shown to affect endothelial functions including EC 
proliferation, migration, and apoptosis. Among them, HDAC5 is anti-angiogenic, as 
HDAC5 knockdown resulted in EC migration and sprouting (12). It appears that HDAC5 
represses a number of angiogenic genes, such as Slit homolog 2 protein (SLIT2) and 
FGF2 (which encodes fibroblast growth factor 2, also known as bFGF), by binding to 
their promoter region (12).  
In this study, we examined the role of HDAC5 in SSc EC impaired angiogenesis. 
We first examined the expression of HDAC5 in ECs isolated from healthy volunteers or 
patients with diffuse cutaneous SSc, and whether knocking it down in SSc ECs altered 
their angiogenic ability. We then utilized an unbiased approach to assess chromatin 
accessibility and identify target genes repressed by HDAC5 in ECs, followed by 
bioinformatics analyses and experimental validation of identified targets. Several 
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HDAC5-regulated genes that play critical role in dysregulated angiogenesis in SSc were 
identified. 
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Materials and Methods 
Patients.  All patients met the American College of Rheumatology/European League 
Against Rheumatism criteria for the classification of SSc (13). The demographics and 
clinical characteristics of the enrolled patients are summarized in Table 1. Two 4mm 
punch biopsies from the distal forearm of healthy volunteers and diffuse cutaneous SSc 
patients were obtained for EC isolation. All subjects included in this study signed a 
written informed consent. All procedures in this study were reviewed and approved by 
the Institutional Review Board of the University of Michigan.  
Cell culture. Dermal ECs were isolated and characterized in our laboratory as 
previously described (4, 6). After digestion ECs were purified using the CD31 
MicroBead Kit and a MiniMACS™ Separator with an MS Column (Miltenyi Biotech) and  
grown in EBM-2 media with growth factors (Lonza). Cells between passage 3 and 6 
were used in the experiments.  
mRNA extraction and qRT-PCR. Total RNA from cells was isolated using Direct-zol™ 
RNA MiniPrep Kit (Zymo Research) or RNeasy Mini kit (Qiagen). Verso cDNA synthesis 
kit was used to prepare cDNA (Thermo Scientific). Primers for human HDAC4, 5, 6, 7, 9, 
and 10, VEGF, and β-actin along with Power SYBR Green PCR master mix (Applied 
Biosystems) were applied for qPCR, which was run by either the ViiA™ 7 Real-Time 
PCR System or the Applied Biosystems Real-Time PCR System. Primer sequences are 
as follows: HDAC4 FW:TGTACGACGCCAAAGATGAC; RV: 
CGGTTCAGAAGCTGTTTTCC; HDAC5 FW: CAGCAGGCGTTCTACAATGA; RV:  
CGATGCAGAGAGATGTAGAGCA; HDAC6 FW: GAAAGTCACCTCGGCATCAT; RV: 
TAGTCTGGCCTGGAGTGGAC; HDAC7 FW: ATGGGGGATCCTGAGTACCT; RV: 
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GATGGGCATCACGACTATCC; HDAC9 FW: CTGGAGCCCATCTCACCTT; RV: 
TCATCATCCTGAGGTCTGTCC; HDAC10 FW:  GCCGGATATCACATTGGTTC; RV: 
GACGCTTCCTGTTGGATGA; VEGF FW: ATGAACTTTCTGCTGTCTTGGGT; RV: 
TGGCCTTGGTGAGGTTTGATCC; β-actin FW: GTCAGGCAGCTCGTAGCTCT; RV: 
GCCATGTACGTTGCTATCCA. The rest of the primers were KiCqStart® SYBR® Green 
Primers from Sigma. 
Western blots. Cell lysate was obtained from both healthy subjects and SSc patients. 
Equal amounts of protein were separated by SDS-PAGE and electroblotted onto 
nitrocellulose membranes. HDAC5 proteins were detected using anti-human HDAC5 
antibodies (Cell Signaling) while β-actin was used as a loading control (anti-β-actin 
antibodies were from Sigma Aldrich). Band quantification was performed using 
GelQuant.NET (BiochemLab Solutions). 
Gene knockdown experiments. To evaluate the effect of HDAC5 on angiogenesis in 
SSc ECs, its expression was knocked down using HDAC5 siRNA from Santa Cruz 
Biotechnology. siRNA from Life Technologies was used as control. We first utilized 
healthy ECs to establish the transfection condition. ECs were transfected with 25-75 nM 
of siRNA with TransIT-TKO transfection reagent (Mirus Bio) for 48 hours and 
mRNA/protein lysate was collected. We then confirmed the knockdown of HDAC5 using 
SSc ECs. The knockdown condition was also optimized for PVRL2 (50nM), CTNNAL1 
(50nM), FSTL1 (25nM), FSTL3 (25nM), (siRNA from Santa Cruz Biotechnology), ID2 
(150nM), and CYR61 (25nM), (siRNA from GE Dharmacon).  
Gene overexpression experiments. Overexpression of PVRL2, FSTL1, and CYR61 
was performed as previously described with some modification (4). ECs were 
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transfected with 0.33 µg of FSTL1, PVRL2 (both from Origene; control vector pCMV6-
XL5), or 1.65 µg of CYR61 (Origene; control vector pCMV6-XL4) and lipofectamine 
2000 (Invitrogen) for 24 hours in T12.5 flasks. Five hours after transfection, the culture 
media was changed to allow the cells to grow in EGM supplemented with bovine brain 
extract (Lonza). Subsequent analysis for qPCR or Matrigel tube formation assay was 
performed. 
Enzyme-linked immunosorbent assay (ELISA). The levels of VEGF and bFGF in cell 
culture supernatants were measured using ELISA kits from R&D systems. The 
absorbance of each well was read using a microplate reader at 450 nm.   
Matrigel tube formation assay. The Matrigel tube formation assay was performed to 
evaluate the effect of HDAC5 on angiogenesis (6). Transfected SSc ECs were 
suspended in EBM-2 with 0.1% fetal bovine serum and plated in 8-well Lab-Tek 
chambers coated with growth factor reduced Matrigel (BD Biosciences). The cells were 
fixed and stained after overnight incubation. Quantitation of the tubes formed by ECs 
was performed by a blinded researcher. Pictures of each well were taken using EVOS 
XL Core C ll Imaging System (Life Technologies). In the case of the double knockdown 
study, SSc ECs were transfected with control siRNA, HDAC5 siRNA, or HDAC5 plus 
the siRNA of genes of interest for 48 hours, and then plated on Matrigel. For the 
overexpression experiments, SSc ECs were transfected with control vector, FSTL1, 
PVRL2, or CYR61 and the Matrigel assay was carried out the next day. 
Assay for transposase-accessible chromatin using sequencing (ATAC-seq). To 
characterize the impact of HDAC5 knockdown on chromatin accessibility at a genome-
wide level, ATAC-seq was performed (14). This utilizes a hyperactive Tn5 transposase 
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that simultaneously cuts and ligates adaptors at regions of open chromatin. Since 
HDAC5 knockdown alters the chromatin structure, application of ATAC-seq in this study 
allowed us to assess genome-wide chromatin accessibility in SSc ECs with high degree 
of accuracy and sensitivity. After transfection, 50,000 ECs were collected and lysed in 
50 µL lysing buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% IGEPAL 
CA-630). After centrifugation the supernatant was discarded and the pellet was used for 
transposition. The transposition reaction included 25 µL 2x TD buffer (Illumina, San 
Diego, CA), 2.5 µLTn5 transposase (Illumina, San Diego, CA), and 22.5 µL water. The 
mixture was incubated at 37oC for 30 min. After purification, DNA libraries were 
prepared by PCR and purified using a Qiagen MinElute Kit. To assess the quality DNA 
libraries, gel electrophoresis was performed and the DNA was visualized using Omega 
Lum C (Aplegen Inc). Libraries that passed quality control measures as previously 
described (14) were sequenced with 50bp, pair-end reads on the Illumina Hi-Seq 2500 
platform (three samples per lane).  
ATAC-seq data analysis. Sequencing reads were aligned to the human genome 
assembly (hg19) using BWA (v0.7.5) (15). Improperly-paired alignment and alignment 
with mapping quality less than 4 were filtered using SAMtools (v0.1.19) (16). Peak-
calling was then performed using MACS2 (v2.0.10) (17), with reads shifted and 
extended by the parameters “--nomodel --shift -100 --extsize 200 -B --broad”. 
Blacklisted genomic regions (18) were removed from the peaks. Comparison between 
HDAC5 knockdown and control was performed using diffReps (v1.55.4) (19), with the 
three individuals treated as triplicates for each condition. Running diffReps with negative 
binomial model and 1e-4 p-value threshold identified peaks that have significantly 
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different signal abundance between the two conditions, with a p-value of less than 0.05 
after being adjusted by the Benjamini-Hochberg method.  
Bioinformatics analysis. To identify genes that are relevant to SSc, genes with 
differential chromatin accessibility with HDAC5 knockdown in ECs were subjected to 
bioinformatics analysis using IRIDESCENT (20). This analysis searches for co-
occurrence of the genes and the key words (i.e. fibrosis or angiogenesis) within the 
scientific literature. A statistical method was used to score the relevance of the co-
occurrence by comparing the observed frequencies to ones randomly occurring by 
chance (20). 
Statistical analysis. Results were expressed as mean ± S.D. To determine the 
differences between the groups in Figure 1, Mann-Whitney U test was performed using 
GraphPad Prism version 6 (GraphPad Software, Inc). To compare the biomarkers 
before and after HDAC5 knockdown in Table 3, a paired t-test was performed. P-values 
of less than 0.05 were considered statistically significant. 
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Aberrant expression of class II HDACs in SSc ECs. We examined the expression of 
class IIa and IIb HDACs using qPCR. As shown in Figure 1A, HDAC4 and 5, both class 
IIa HDACs, were upregulated in SSc ECs compared to control ECs, while HDAC6, a 
class IIb HDAC, was downregulated (p<0.05). We further confirmed increased HDAC5 
expression in SSc ECs at the protein level (Figure 1B). Although HDAC5 expression 
was variable among SSc patients, there was a significant increase in HDAC5 
expression in SSc ECs (p<0.05, n=4). Since HDAC5 is anti-angiogenic, we proceeded 
to knockdown HDAC5 and examined whether the decrease in HDAC5 altered the 
angiogenic ability of SSc ECs. We first established the HDAC5 knockdown condition 
(Figure 1C). In healthy ECs, 75 nM of HDAC5 siRNA resulted in approximately 70% 
knockdown of HDAC5 compared to cells transfected with control siRNA. We used this 
condition in SSc ECs and achieved approximately 87% knockdown. Under this 
condition, we confirmed that at the protein level, HDAC5 was indeed negligible (Figure 
1D). Therefore in subsequent experiments the condition we used for HDAC5 
knockdown was to use 75 nM siRNA for 48 hours.  
HDAC5 knockdown increased tube formation in SSc ECs. We then tested whether a 
decrease in HDAC5 expression altered the angiogenic ability of SSc ECs using the 
Matrigel tube formation assay. We first used ECs isolated from healthy subjects and 
SSc patients and performed Matrigel tube formation assay. Similar to previous reports 
(3, 5, 7), in the absence of an angiogenic stimulus SSc ECs were unable to form tube-
like structures on Matrigel, while healthy ECs could (Figure 1E). SSc ECs transfected 
with control siRNA also demonstrated a diminished capability to form tubes (Figure 1F). 
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In contrast, knocking down HDAC5 restored the ability of SSc EC to form tubes and 
resulted in approximately a two fold increase in the number of tubes formed (p<0.05). 
ATAC-seq revealed differential open-chromatin regions after HDAC5 knockdown 
in SSc ECs. HDAC5 knockdown showed increased chromatin accessibility compared to 
control siRNA-treated cells (Figure 2A). A total of 119 regions were identified with at 
least a 20% fold difference (≥1.2 fold or ≤0.80 fold) in chromatin accessibility, 
represented by a change in sequencing peak intensity (adjusted p-value <0.05). Of 
those, there were 85 regions with increased chromatin accessibility, and 34 regions with 
decreased chromatin accessibility. In the regions of increased chromatin accessibility, 
we identified a total of 75 genes located in these sites (Figure 2A). In contrast, only 9 
genes were located in less-accessible regions. The genes that were located in the more 
accessible regions that had a 1.5 fold increase in peak intensity between HDAC5 
knockdown and control were listed in Table 2. Figure 2B shows genome tracks of the 
FSTL3 locus. Knockdown of HDAC5 increased chromatin accessibility as indicated by 
the increase in peak intensity compared to control-siRNA treated cells. For validation we 
compared our ATAC-seq data with chromatin-accessibility data sets such as DNase-
seq. The ATAC-seq peaks correlated with DNases hypersensitivity regions generated in 
human umbilical ECs (HUVECs, generated by University of Washington ENCODE 
group). In addition, we observed that ATAC-seq data aligned with ChIP-seq peaks from 
the ENCODE project (21) for histone marks associated with active chromatin (H3K27ac).  
Up-regulation of genes involved in angiogenesis or fibrosis after HDAC5 
knockdown. Bioinformatics analysis using IRIDESCENT revealed that among genes 
that are located in the regions of increased chromatin accessibility in SSc ECs after 
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HDAC5 knockdown, at least 16 genes might be involved in angiogenesis and a few 
involved in fibrosis (Figure 2C). Three genes were identified as possibly involved in both 
angiogenesis and fibrosis (CYR61, KRAS, and SOD2). We then examined the 
expression of the genes listed in Figure 2C in SSc ECs before and after HDAC5 
knockdown. We found 8 genes to be significantly upregulated (Table 3, p<0.05). These 
include ID2, MBP, PVRL2, CTNNAL1, FSTL3, SQSTM1, CYR61, and FSTL1. In 
addition to the genes identified by ATAC-seq, we also examined the expression of two 
pro-angiogenic factors, VEGF and bFGF. As shown in Figure 3A, both VEGF and bFGF 
mRNA levels were significantly upregulated after HDAC5 knockdown. We also 
observed 1.5 to 2-fold increase in protein levels of both VEGF and bFGF in SSc ECs 
culture supernatants after HDAC5 knockdown (data not shown).  
Identification of genes that play functional roles in HDAC5-mediated 
angiogenesis. We performed double knockdown experiments to identify genes that led 
to increase in tube formation after HDAC5 knockdown. We chose angiogenic genes that 
were significantly upregulated after HDAC5 knockdown, as listed in Table 3. This 
included ID2, PVRL2, CYR61, and CTNNAL1. In addition, FSTL1 and FSTL3 are also 
included since upon comprehensive literature search, they appear to be pro-angiogenic. 
MBP was excluded as we were unable to identify its role in angiogenesis. As shown in 
Figure 3B, in SSc ECs, when FSTL1, PVRL2, or CYR61 were knocked down together 
with HDAC5, the number of tubes on Matrigel decreased, while transfecting the cells 
with ID2, FSTL3 or CTNNAL1 siRNA had minimal effect, suggesting that HDAC5 
mediated its anti-angiogenic effect at least in part through changing chromatin 
accessibility of FSTL1, PVRL2, and CYR61. To further confirm their roles, we 
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overexpressed FSTL1, PVRL2, or CYR61 individually in SSc ECs and showed that 
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 In this study, we identified a novel epigenetic mechanism that contributes to the 
inhibition of angiogenesis in SSc. HDAC5, which was overexpressed in SSc ECs, 
inhibited angiogenesis by repressing pro-angiogenic genes. This was achieved by 
applying ATAC-seq to assess changes in the chromatin state after HDAC5 knockdown, 
thereby identifying key genes located in regions with increased chromatin accessibility. 
Several angiogenic and fibrotic-related genes were pinpointed, as their expression 
increased significantly after HDAC5 knockdown. Among the pro-angiogenic genes 
identified by ATAC-seq, we showed that PVRL2, FSTL1, and CYR61 played critical 
roles in promoting angiogenesis in SSc ECs, as overexpression of these genes resulted 
in increase in tube formation by SSc ECs, while knocking down these genes together 
with HDAC5 led to decrease in tube formation.  
It is apparent that epigenetic changes are involved in SSc vasculopathy, as in 
this study, we showed that HDAC5 was involved in impaired angiogenesis in SSc ECs. 
Indeed our results complement the work in fibrosis, where it was shown that histone 
acetylation patterns differed in SSc patients and that the use of HDAC inhibitors showed 
promising anti-fibrotic effect both in vivo and in vitro (22, 23). However, global 
inactivation of HDACs by nonspecific inhibitors may affect angiogenesis by modifying 
both pro- and anti-angiogenic HDACs. These pan-HDAC inhibitors target class I, II 
and/or IV HDACs that govern cell proliferation, differentiation, migration, and 
angiogenesis. They inhibit angiogenesis through VEGF and hypoxia-inducible factor (24, 
25), affect class IIb HDAC-mediated cell migration, and induce class I HDAC-mediated 
cell apoptosis (26). Therefore one should be cautious when using HDAC inhibitors to 
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treat fibrosis in SSc, as this may be detrimental to the vasculopathic component of this 
disease.  
 Our results agree with the study by Ulbich et al. in that HDAC5 knockdown led to 
increase in tube formation by ECs on Matrigel (12). They showed that target genes 
regulated by HDAC5 include FGF2, SLIT2, and EPHB4. We showed that bFGF 
(encoded by FGF2) was upregulated after HDAC5 knockdown (Figure 3A), and also 
identified additional genes that are repressed by HDAC5, including PVRL2, FSTL1 and 
CYR61 (Table 3). The discrepancies between the two studies might be due to the 
different type of ECs used. The methods that were applied to identify genes were also 
different (ATAC-seq vs. oligonucleotide array). Of note, the discrepancy between bFGF 
and VEGF expression and the ATAC-seq results may seem contradictory; however, it is 
not uncommon for chromatin accessibility and gene expression not to correlate with 
each other. As shown in Table 3, only 8 of the 25 genes that showed significant 
increase in chromatin accessibility had increased mRNA expression. These results 
point to the importance of studying the epigenome and transcriptome simultaneously, as 
the integration of data obtained from both approaches would greatly facilitate target 
gene identification.  
We identified several pro-angiogenic factors controlled by HDAC5 (Table 3). 
CYR61 (also known as CCN1) is a member of the CCN protein family that binds to the 
extracellular matrix and supports angiogenesis (27). In contrast to CCN2 (also known as 
CTGF, connective tissue growth factor) which is pro-fibrotic, CYR61 is antifibrotic 
through activation of an integrin/oxidative stress-mediated pathway (28). Saigusa et al 
showed that CYR61 is downregulated in dermal small blood vessels of SSc patients 
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compared to controls (29). We postulate that the anti-fibrotic nature of this molecule 
should also play a significant role in inhibiting the fibrotic process in SSc, since it has 
been shown that CYR61 restricted fibrosis in several models of fibrosis including the 
skin (28, 30, 31). However the role of CYR61 in SSc fibrosis awaits further investigation. 
The role of FSTL1 in fibrosis is shown mainly in pulmonary fibrosis; depletion or 
blockade of FSTL1 in mice attenuated bleomycin-induced lung fibrosis (32). However, 
contradicting results were obtained in a renal fibrosis mouse model (33). Although our 
bioinformatics analysis showed that FSTL1 played a role solely in fibrosis (Figure 2C), 
upon a more detailed literature search, we found that it is also involved in EC 
proliferation and tube formation (34). Although its role in SSc pathogenesis remains to 
be explored, it has been shown that FSTL1 is elevated in SSc serum (35). In this study, 
we showed that the expression of FSTL1 increased after HDAC5 knockdown, agreeing 
with a previous study showing that FSTL1 is regulated by histone acetylation (36).  
 PVRL2 is a cell adhesion molecule that connects to the actin cytoskeleton by 
binding to afadin (37). The mechanism of how nectin-2 promotes angiogenesis is not 
known. It is possible that it is mediated directly by its cell adhesion properties, but also 
indirectly through afadin, which promotes angiogenesis (38), or through interacting with 
other members of adhesion molecules (39). As adhesion molecules have been 
suggested to play a role in SSc pathogenesis (2), our finding that PVRL2 improves the 
angiogenic ability of SSc ECs offers new insights as how these adhesion molecules are 
involved in this disease. 
It appears that HDAC5 also controls fibrosis through SSc ECs, as a few fibrotic 
genes, including FSTL1, FSTL3, and SQSTM1, were identified to be upregulated after 
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HDAC5 knockdown in our study (Table 3). These genes are involved in the TGFβ  
(FSTL1 and FSTL3) and autophagy pathways (SQSTM1) (40, 41). FSTL3 also plays a 
role in angiogenesis through inhibiting activin A (42, 43). However in our study, 
simultaneous knockdown of HDAC5 and FSTL3 did not reverse the angiogenic 
phenotype of SSc ECs. Although autophagy has been shown to play a role in various 
fibrotic disorders including SSc (44, 45), whether SQSTM1 is critical warrants additional 
studies.  
In addition to its role in angiogenesis, HDAC5 appears to be involved in 
inflammation and immunity. It controls the inflammatory responses of macrophages and 
T cell functions (46, 47). In addition, HDAC5 negatively regulates chemokine and 
cytokine production in fibroblast-like synoviocytes in rheumatoid arthritis (48). Therefore, 
it is also possible that HDAC5 has functional roles in the inflammatory and autoimmune 
aspect of SSc pathogenesis. 
In conclusion, our results clearly show that epigenetic mechanisms contribute 
significantly to impaired angiogenesis in SSc. Increased expression of anti-angiogenic 
HDAC5 repressed several pro-angiogenic genes resulting in dysregulated angiogenesis 
in SSc ECs. Coupling ATAC-seq with functional assays, we identified novel angiogenic 
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Figure 1. The effect of HDAC5 expression on the angiogenic ability of SSc ECs. (A) 
The expression of HDAC4 and HDAC5, both class IIa HDACs, was significantly 
elevated in SSc ECs compared to healthy ECs, while class IIb HDAC6 was down-
regulated (p<0.05). (B) HDAC5 protein levels were upregulated in SSc patients 
compared to healthy controls. (C) HDAC5 was knocked down in both healthy and SSc 
ECs. The use of 75 nM of HDAC5 siRNA resulted in more than 70% knockdown in both 
cell types. (D) HDAC5 knockdown was confirmed at the protein level. (E) SSc ECs were 
unable to form tubes on Matrigel while normal ECs spontaneously form tubes, showing 
the anti-angiogenic nature of SSc ECs. (F) Knockdown of HDAC5 in SSc ECs led to 
increased tube formation on Matrigel. Quantification of the tubes was done by counting 
the tubes by a blinded investigator. Significant increase in tube formation after HDAC5 
knockdown was observed (p<0.05). n=3 patient lines. Results are expressed as mean 
+/- SD and p<0.05 was considered significant. 
 
Figure 2. ATAC-seq revealed differential open-chromatin regions after HDAC5 
knockdown in SSc ECs. (A) HDAC5 knockdown increased chromatin accessibility 
compared to control siRNA transfected cells. With a cut-off of 20% change with a p-
value adjusted for multiple testing less than 0.05, we identified a total of 119 regions: 85 
of them were regions with increased chromatin accessibility, and 34 were regions with 
decreased chromatin accessibility. In the regions of increased chromatin accessibility, 
75 genes were located in these sites and only 9 genes were located in less-accessible 
regions. (B) UCSC genome browser tracks of the FSTL3 locus with data of ATAC-seq 
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signals from control or HDAC5 siRNA treated samples, DNase I hypersensitivity 
mapping from human umbilical endothelial cells (HUVECs, generated by the ENCODE 
project), as well as H3K27ac ChIP (HUVECs, ENCODE). HDAC5 knockdown resulted 
in increase in peak intensity compared to control siRNA. The ATAC-seq signals were 
very similar compared to DNase I hypersensitivity sequencing and overlapped H3K27ac 
enrichment in HUVECs. (C) Genes located in the more-accessible chromatin regions 
after HDAC5 knockdown were analyzed using IRIDESCENT to identify genes that were 
related to angiogenesis or fibrosis.  
 
Figure 3. Several upregulated pro-angiogenic factors promote tube formation 
after HDAC5 knockdown. (A) The expression of VEGF and bFGF was quantified by 
qPCR. Increased expression was observed in both cases after HDAC5 knockdown. (B) 
Matrigel tube formation was performed after diffuse cutaneous SSc ECs were 
transfected with siRNA of control, HDAC5, or HDAC5 plus genes of interest. PVRL2, 
FSTL1, and CYR61 appeared to play key role in promoting angiogenesis after HDAC5 
knockdown, while FSTL3, ID2, and CTNNAL1 did not. n=4 patient lines. (C) 
Overexpression of PVRL2, FSTL1, and CYR61 resulted in increase in tube formation by 
SSc ECs. Results are expressed as mean +/- SD and p<0.05 was considered 
significant.  
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Age (years) 50.9 ± 4.2
a
 49.8 ± 5.0 
Sex F10/M2 F6/M2 
Diffuse SSc 12 N.A.
b
 
Disease duration (years) 3.4 ± 0.7 N.A. 
Modified Rodnan Skin Score  14.3 ± 2.6 N.A. 
Raynaud’s phenomenon 12 N.A. 
Early disease (< 5yrs) 10 N.A. 
Digital ulcers 2 N.A. 
Teleangectasias 7 N.A. 
Gastrointestinal disease 9 N.A. 
Interstitial lung disease 9 N.A. 
Pulmonary arterial hypertension 4 N.A. 
Renal involvement 1 N.A. 
a
Mean ± SEM   
b
N.A. = Not applicable    
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Table 2: Genes located in regions with at least 1.5 fold increase in chromatin 











chr19 680601-681600 FSTL3 2.17 9.32E-06 8.14E-04 
chr7 156930501-156931700 UBE3C 1.93 2.96E-06 3.57E-04 
chr13 52979801-52980900 THSD1 1.84 1.54E-06 2.48E-04 
chr21 47604401-47605600 C21orf56 1.83 2.43E-06 3.32E-04 
chr1 156697701-156698700 RRNAD1 1.77 8.04E-05 3.91E-03 
chr12 9066701-9067700 PHC1 1.75 4.40E-06 4.95E-04 
chr11 134122401-134124000 THYN1 1.73 3.93E-06 4.49E-04 
chr17 77070501-77071500 ENGASE 1.73 6.03E-05 3.26E-03 
chr14 96570401-98571900 - 1.72 1.61E-06 2.48E-04 
chr3 120169201-120170200 FSTL1 1.65 1.09E-05 9.27E-04 
chr3 49058601-49059800 NDUFAF3 1.64 2.04E-06 3.08E-04 
chr6 74363001-74364300 SLC17A5 1.62 2.79E-05 1.93E-03 
chr2 238600001-238601100 LRRFIP1 1.61 1.13E-05 9.53E-04 
chr5 179233401-179234700 SQSTM1 1.61 2.70E-06 3.49E-04 
chr1 86045601-86047200 CYR61 1.60 2.31E-06 3.27E-04 
chr17 61698601-61699700 MAP3K3 1.60 8.41E-06 7.55E-04 
chr17 38108801-38109900 - 1.59 9.42E-05 4.43E-03 
chr19 45348901-45349900 PVRL2 1.57 2.79E-06 3.49E-04 
chr2 26256501-26257700 RAB10 1.56 9.68E-05 4.45E-03 
chr5 40834901-40835900 RPL37 1.56 8.95E-05 4.25E-03 
chr12 109219701-109220800 SSH1 1.55 3.23E-05 2.14E-03 
chr2 112811101-112812900 TMEM87B 1.54 2.56E-05 1.85E-03 
chr7 105752501-105753600 SYPL1 1.54 1.19E-05 9.77E-04 
chr9 95895401-95896500 NINJ1 1.54 2.45E-06 3.32E-04 
chr6 160114401-160115600 SOD2 1.53 2.74E-06 3.49E-04 
chr9 77702101-77703100 C9orf95 1.53 2.28E-06 3.27E-04 
chr11 112096901-112098000 PTS 1.52 8.11E-06 7.37E-04 
chr12 22696601-22697600 KIAA0528 1.52 8.08E-05 3.91E-03 
chr20 57267501-57268600 NPEPL1 1.52 2.22E-04 9.74E-03 
chr1 171710501-171711500 VAMP4 1.51 3.49E-05 2.27E-03 
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Table 3: mRNA expression levels of candidate genes after HDAC5 knockdown in 



















Expression fold change vs. control 
(n=7 patient pairs) 
p-value 
ID2 2.188 ± 1.002 0.02 
CTNNAL1 2.064 ± 0.880 0.03 
MBP 4.073 ± 5.550 0.03 
PVRL2 3.091 ± 1.600 0.02 
CYR61 2.423 ± 1.562 0.03 
FSTL1 2.542 ± 1.514 0.04 
FSTL3 4.586 ± 4.358 0.03 
SQSTM1 2.080 ± 1.419 0.04 
KRAS 1.884 ± 1.250 0.08 
SOD2 3.446 ± 2.591 0.08 
NINJ1 1.849 ± 1.469 0.55 
THSD1 1.762 ± 1.106 0.43 
FGF18 1.023 ± 1.576 0.35 
FAM198 1.086 ± 0.793 0.86 
TAB2 1.532 ± 1.017 0.75 
TMEM18 1.339 ± 0.688 0.99 
IQSEC1 1.301 ± 0.661 0.22 
NFYA 1.757 ± 1.622 0.19 
ETV5 2.453 ± 2.228 0.83 
EDEM1 1.342 ± 0.685 0.35 
HSF2 1.807 ± 1.062 0.14 
MAP3K3 1.417 ± 0.898 0.55 
PRDX3 1.365 ± 0.664 0.31 
HSPA2 1.152 ± 0.720 0.31 
MATN1 N.D.  
N.D.=Not Detected 
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